(Q36788418)

16 August 2017

1 reference

title

Whole-body physiologically based pharmacokinetic models (English)

1 reference

16 August 2017

1 reference

Ivan Nestorov

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

235-249

1 reference

Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

The use of in vitro data in risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Toxicokinetic modeling and its applications in chemical risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Whole body pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

The use and abuse of models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological modelling of organic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Lumping of whole-body physiologically based pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Lumping in pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Evaluation of Physiologically Based Models of Pregnancy and Lactation for Their Application in Children's Health Risk Assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Predicting Fetal Perchlorate Dose and Inhibition of Iodide Kinetics during Gestation: A Physiologically-Based Pharmacokinetic Analysis of Perchlorate and Iodide Kinetics in the Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic modeling of the lactational transfer of methylmercury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Structural identifiability of physiologically based pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Use of allometry in predicting anatomical and physiological parameters of mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Metabolic rate constants for hydroquinone in F344 rat and human liver isolated hepatocytes: application to a PBPK model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

An integrated approach to model hepatic drug clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Analysis of solvent central nervous system toxicity and ethanol interactions using a human population physiologically based kinetic and dynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Simulation of toluene kinetics in the rat by a physiologically based pharmacokinetic model with application of biotransformation parameters derived independently in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Prediction of in vivo tissue distribution from in vitro data 1. Experiments with markers of aqueous spaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological Approaches to the Prediction of Drug-Drug Interactions in Study Populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

ADMET in silico modelling: towards prediction paradise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

In silico prediction of harmful effects triggered by drugs and chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Analysis of algorithms predicting blood:air and tissue:blood partition coefficients from solvent partition coefficients for prevalent components of JP-8 jet fuel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Determination of the rat tissue partitioning of endotoxin in vitro for physiologically-based pharmacokinetic (PBPK) modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Quantitative structure-property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Comparison of models for the estimation of biological partition coefficients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Determination of tissue-blood partition coefficients for a physiological model for humans, and estimation of dioxin concentration in tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A spreadsheet program for modeling quantitative structure-pharmacokinetic relationships for inhaled volatile organics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Quantitative structure-pharmacokinetic relationship modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: a sensitivity analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Optimal design for multivariate response pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

On the importance of exposure variability to the doses of volatile organic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Pharmacokinetic model-predicted anticancer drug concentrations in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Population pharmacokinetic studies in pediatrics: issues in design and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

The Bayesian population approach to physiological toxicokinetic-toxicodynamic models--an example using the MCSim software

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A physiologically based pharmacokinetic (PB/PK) model for multiple exposure routes of soman in multiple species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: analysis using PBPK models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Quantitative risk analysis of particulate matter in the air: interspecies extrapolation with bioassay and mathematical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Interspecies dose extrapolation for inhaled dimethyl sulfate: a PBPK model-based analysis using nasal cavity N7-methylguanine adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Development of a physiologically based pharmacokinetic model for propylene glycol monomethyl ether and its acetate in rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Evaluation of the dermal bioavailability of aqueous xylene in F344 rats and human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Use of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry comparisons of ester vapors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic model for terbinafine in rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A computer program linking physiologically based pharmacokinetic model with cancer risk assessment for breast-fed infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

An inhalation distribution model for the lactating mother and nursing child.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Development and evaluation of a generic physiologically based pharmacokinetic model for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, and xylene) under resting and working conditions using PBPK modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based modeling of n-hexane kinetics in humans following inhalation exposure at rest and under physical exertion: impact on free 2,5-hexanedione in urine and on n-hexane in alveolar air.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Incorporation of therapeutic interventions in physiologically based pharmacokinetic modeling of human clinical case reports of accidental or intentional overdosing with ethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A physiologically-based pharmacokinetic model of drug detoxification by nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Cerebral kinetics of oxycodone in conscious sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

The acute disposition of (R)- and (s)-methadone in brain and lung of sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs - method development and application to magnesium in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A physiologically based pharmacokinetic model for oxytetracycline residues in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A physiologically based toxicokinetic model for dietary uptake of hydrophobic organic compounds by fish: I. Feeding studies with 2,2',5,5'-tetrachlorobiphenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

The development of a physiologically-based pharmacokinetic model using the distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the tissues of the eastern oyster (Crassostrea virginica).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Dynamical coupling of PBPK/PD and AUC-based toxicity models for arsenic in tilapia Oreochromis mossambicus from blackfoot disease area in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Momentary brain concentration of trichloroethylene predicts the effects on rat visual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Chloroform: exposure estimation, hazard characterization, and exposure-response analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Validation of human physiologically based pharmacokinetic model for vinyl acetate against human nasal dosimetry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Direct reconstruction of kinetic parameter images from dynamic PET data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Pharmacokinetics of ethylene in man by on-line laser photoacoustic detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

Physiologically based pharmacokinetics modeling: science and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A Physiologically Based Pharmacokinetic Description of the Oral Uptake, Tissue Dosimetry, and Rates of Metabolism of Bromodichloromethane in the Male Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.2.235

21 January 2018

Identifiers

DOI

10.1517/17425255.3.2.235

1 reference

16 August 2017

1 reference